Santen is partnering with the International Agency for the Prevention of Blindness to implement United Nations General Assembly Resolution A/75/L.108, focusing on eye health and sustainable development, according to a press release. The resolution “encourages governments and key stakeholders from around the world to mobilize the necessary resources to address this urgent priority,” the release said.
New telemedicine approach may allow for remote treatment of DR
A novel telemedicine approach combining the high speed of 5G wireless networks and navigated retinal laser photocoagulation could allow treatment of diabetic retinopathy at a distance.
Rayner Announces 1,000 IOLs Recorded on RayPRO Digital Platform
Rayner announced that it has achieved the milestone figure of 1,000 intraocular lenses recorded on RayPRO, its digital patient reported outcomes platform.
Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercept
Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.
Voptica Introduces First Inverted Meniscus IOL to Improve Peripheral Vision
Voptica SL plans to announce the first and only inverted meniscus intraocular lens (ArtIOLs) to improve peripheral vision at the 2021 ESCRS Satellite Symposium in Amsterdam on October 8.
Aldeyra Therapeutics Receives Orphan Drug Designation from the FDA for ADX-2191 to Treat Retinitis Pigmentosa
Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP).
Eyevensys Raises $12M in a Series B Plus Funding Round
Eyevensys announced it has raised $12 million in a Series B Plus funding round. Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
Adjustable IOL Maker RxSight Launches $118 Million IPO
RxSight, of Aliso Viejo, California, launched on July 30 a $118 million initial public offering of 7.35 million shares of common stock at a price of $16 per share. Shares are trading on the Nasdaq under the symbol RXST.
Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
Harrow Health, Inc. announced that it has entered into an agreement with Sintetica to acquire the marketing and supply rights in the U.S. and Canada for AMP 100, a patented ophthalmic surgical drug candidate.
Study Shows Reduction in Postoperative Halos in Patients Treated With Tearscience Lipiflow Treatment Prior to Bilateral Cataract Surgery
Johnson & Johnson Vision revealed new comparative clinical study findings evaluating TearScience LipiFlow treatment in cataract surgery. The data concluded that treating patients with TearScience LipiFlow prior to cataract surgery significantly reduced patient-reports of halos compared to control group (58.6 vs. 79 percent) and showed larger improvements in Meibomian Gland Score (MGD) than control group (107 vs. 66 percent).